Plasma proBNP measurement showed high diagnostic performance for detecting LVEF <40% in the general population, with an AUC of 0.92 (95% CI 0.79-1.00) in women and 0.85 (95% CI 0.74-0.96) in men.
Cohort (n=3,497)
Does plasma proBNP measurement accurately detect left ventricular hypertrophy and systolic dysfunction in the general population?
Plasma proBNP measurement demonstrates high diagnostic accuracy for detecting severe left ventricular systolic dysfunction (LVEF <40%) in the general population, paralleling known data for BNP.
Effect estimate: AUC 0.92 in women, 0.85 in men (95% CI 0.79-1.00 in women, 0.74-0.96 in men)
AIMS: B-type natriuretic peptide (BNP) measurement in screening for left ventricular hypertrophy (LVH) and left ventricular systolic dysfunction (LVSD) has been evaluated in the general population, but corresponding information on proBNP and the N-terminal proBNP fragment is still limited. We therefore examined whether proBNP measurement is useful for LVH and LVSD screening in the general population. METHODS AND RESULTS: In the 4th Copenhagen City Heart Study, 3497 participants underwent echocardiography with assessment of left ventricular ejection fraction (LVEF) and mass. The impact of gender and age was determined and the diagnostic performance of the plasma proBNP concentration was evaluated using receiver operating characteristic (ROC) curves. Of 1502 men and 1995 women, 4.1 and 2.6% had LVSD defined as an LVEF<60% whereas only 0.4% displayed LVEF<40%. The proBNP concentration was 1.7-fold higher in women compared with men (P<0.0001) and related to age in both genders. The mean proBNP plasma concentration was two-fold higher in subjects with LVSD than without LVSD (P<0.0001). Likewise, LVH imposed a 1.9-fold increase in the proBNP concentration (P<0.0001): Both differences persisted after adjusting for ischaemic heart disease, hypertension, diabetes, gender, and age. The diagnostic performance of proBNP in detecting LVEF<40% was high with an area under the ROC curves of 0.92 (95% CI 0.79-1.00) in women and 0.85 (95% CI 0.74-0.96) in men. CONCLUSION: We have established the impact of age and gender on the proBNP concentration in a large, community-based cohort. The diagnostic performance for proBNP measurement in screening for LVH and LVSD in the general population parallels the reported data for BNP.
Goetze et al. (Fri,) conducted a cohort in Left ventricular hypertrophy and systolic dysfunction (n=3,497). Plasma proBNP measurement was evaluated on Detection of LVEF <40% (AUC 0.92 in women, 0.85 in men, 95% CI 0.79-1.00 in women, 0.74-0.96 in men). Plasma proBNP measurement showed high diagnostic performance for detecting LVEF <40% in the general population, with an AUC of 0.92 (95% CI 0.79-1.00) in women and 0.85 (95% CI 0.74-0.96) in men.